Clesrovimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | MK-1654 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Clesrovimab (MK-1654) is a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infections. Developed by Merck, it is in a phase III trial as of 2023. It works differently than nirsevimab.[1][2][3][4][5][6][7][8]
References[edit]
- ^ Odumade, Oludare A; van Haren, Simon D; Angelidou, Asimenia (15 August 2022). "Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection". Clinical Infectious Diseases. 75 (Supplement_1): S130–S135. doi:10.1093/cid/ciac373. PMC 9129219. PMID 35579506.
- ^ Dolgin, Elie (27 September 2023). "Antibody therapies set to transform respiratory syncytial virus prevention for babies". Nature. 621 (7980): S55–S57. doi:10.1038/d41586-023-02957-z. PMID 37758887. S2CID 262894944.
- ^ Verwey, Charl; Madhi, Shabir A. (May 2023). "Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus". BioDrugs. 37 (3): 295–309. doi:10.1007/s40259-023-00596-4. PMC 10127166. PMID 37097594.
- ^ Cunningham, Steve; Zar, Heather J. (15 June 2023). "New Interventions to Prevent Respiratory Syncytial Virus Disease in Infants—Time for Equitable Global Access". American Journal of Respiratory and Critical Care Medicine. 207 (12): 1556–1557. doi:10.1164/rccm.202303-0568VP. PMC 10273123. PMID 37104655.
- ^ Qiu, Xirui; Xu, Siyan; Lu, Yang; Luo, Zichen; Yan, Yangtian; Wang, Chuyue; Ji, Jianjian (December 2022). "Development of mRNA vaccines against respiratory syncytial virus (RSV)". Cytokine & Growth Factor Reviews. 68: 37–53. doi:10.1016/j.cytogfr.2022.10.001. PMID 36280532. S2CID 252877115.
- ^ Phuah, Jia Yao; Maas, Brian M.; Tang, Aimin; Zhang, Ying; Caro, Luzelena; Railkar, Radha A.; Swanson, Michael D.; Cao, Yu; Li, Hankun; Roadcap, Brad; Catchpole, Andrew P.; Aliprantis, Antonios O.; Vora, Kalpit A. (December 2023). "Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults". Biomedicine & Pharmacotherapy. 169: 115851. doi:10.1016/j.biopha.2023.115851. PMID 37976891. S2CID 265251138.
- ^ Liszewski, Kathy (1 May 2023). "Multiple Vaccine Technologies Converge on Respiratory Syncytial Virus: Advances include a bivalent subunit vaccine, a liposome-based adjuvant, an mRNA vaccine, and a passive vaccination approach". Genetic Engineering & Biotechnology News. 43 (5): 16–18, 20. doi:10.1089/gen.43.05.05. S2CID 258583326.
- ^ Messina, Alessandro; Germano, Chiara; Avellis, Vincenzo; Tavella, Elena; Dodaro, Valentina; Massaro, Alessio; Vitale, Raffaele; Masturzo, Bianca; Manzoni, Paolo (November 2022). "New strategies for the prevention of respiratory syncytial virus (RSV)". Early Human Development. 174: 105666. doi:10.1016/j.earlhumdev.2022.105666. PMID 36174288.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |